Physician profile
Sam Zand
NPI 1528485570
$410,216.72
in general payments reported to CMS, 2019-2025
19 companies · $59K in 2025
The $59K reported for 2025 was more than what 98% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $14K · 2020: $27K · 2021: $54K · 2022: $121K · 2023: $84K · 2024: $51K · 2025: $59K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $128K · Travel and Lodging: $27K · Consulting Fee: $18K · Honoraria: $16K · Food and Beverage: $5,553.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $127,930.00 |
| Travel and Lodging | $26,562.32 |
| Consulting Fee | $17,750.00 |
| Honoraria | $16,475.00 |
| Food and Beverage | $5,552.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $160,075.65 | 2019-2025 | Spravato |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $71,408.45 | 2020-2023 | |
| Otsuka America Pharmaceutical, INC. | $46,945.90 | 2019-2025 | Rexulti |
| Axsome Therapeutics, INC. | $37,359.48 | 2023-2025 | Auvelity |
| Neuronetics, INC. | $25,554.17 | 2019-2023 | Neurostar Tms Therapy System |
| Allergan, INC. | $25,398.07 | 2019-2021 | |
| Abbvie INC. | $19,551.81 | 2021-2024 | Vraylar |
| Teva Pharmaceuticals USA, INC. | $11,221.54 | 2019-2022 | |
| Vanda Pharmaceuticals INC. | $9,966.96 | 2019-2024 | Fanapt |
| Neurocrine Biosciences, INC. | $1,113.49 | 2019-2024 | Ingrezza |
| E.R. Squibb & Sons, L.L.C. | $327.28 | 2024-2025 | Cobenfy |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $252.80 | 2019-2022 | |
| Supernus Pharmaceuticals, INC. | $239.37 | 2021-2023 | Qelbree |
| Abbott Laboratories | $189.87 | 2019 | |
| Boston Scientific Corporation | $159.18 | 2020-2024 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Indivior INC. | $155.28 | 2019 | |
| Alkermes, INC. | $147.91 | 2019-2022 | |
| Dexcom, INC. | $113.67 | 2023 | Dexcom G6 Transmitter |
| Lundbeck LLC | $35.84 | 2019-2023 | Rexulti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sam Zand listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.